Quantum Biopharma (NASDAQ:QNTM) Issues Earnings Results

Quantum Biopharma (NASDAQ:QNTM) released its quarterly earnings data on Thursday. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.06), Zacks reports.

Quantum Biopharma Stock Performance

QNTM stock traded down $0.25 during midday trading on Thursday, reaching $3.23. 223,249 shares of the company traded hands, compared to its average volume of 298,039. The firm has a market capitalization of $20.67 million, a price-to-earnings ratio of -0.39 and a beta of 0.45. Quantum Biopharma has a 52-week low of $2.07 and a 52-week high of $23.66. The business has a 50 day moving average of $3.46 and a 200-day moving average of $4.08.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Weiss Ratings downgraded Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. Wall Street Zen upgraded shares of Quantum Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Quantum Biopharma presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Quantum Biopharma stock. Virtu Financial LLC bought a new stake in Quantum Biopharma Ltd. (NASDAQ:QNTM) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,406 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned 0.27% of Quantum Biopharma at the end of the most recent quarter. Institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.